Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Lol

<< Previous

Bullboard Posts

Next >>

Post by Stutterson Oct 20, 2022 11:33pm

822 Views

Post# 35038076

Lol

My impression of mugsy......Ate is down another 7% today. Hahahaha. Been adding since $7. Hahaha Keep loading up. Ive been loading up since 1954. Hahaha. May take awhile but Ate will pay off. Hahaha...my average is .04 cents hahaha. Your a joke hahaha

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth